Currently, the dual immunotherapy that combines PD-1/PD-L1 and CTLA-4 inhibitors has received approval for various cancer indications, such as the nivolumab + ipilimumab regimen, a combination of PD-1 and CTLA-4 inhibitors. The gene discussed is CD274; the disease is cancer.